FDA approves Beyfortus to protect infants against RSV diseaseBeyfortus is used for the prevention of respiratory syncytial virus lower respiratory tract disease in newborns and infants born during or entering their first RSV season. Sage, Biogen obtain FDA OK for ZurzuvaeZurzuvae is the first oral treatment for postpartum depression. FDA grants traditional approval for Leqembi for the treatment of Alzheimer's disease Leqembi is the only approved treatment shown to reduce the rate of disease progression in adults with Alzheimer's, the company said. Bausch + Lomb to acquire Xiidra from Novartis Xiidra is a prescription eye drop used to treat dry eye disease. Eli Lilly releases phase 2 data from retatrutide study Retatrutide, an investigational molecule being studied for the treatment of obesity, met the primary endpoint for the efficacy estimand in participants. Boehringer Ingelheim, Lilly receive FDA OK for Jardiance Jardiance is now approved to lower blood sugar in children 10 years and older with Type 2 diabetes. Indivior receives FDA nod for Opvee Opvee nasal spray is indicated for the emergency treatment of known or suspected opioid overdose. Otsuka, Lundbeck get FDA OK for new indication for Rexulti Rexulti is now approved for the treatment of agitation associated with dementia due to Alzheimer’s disease. Viatris publishes sustainability report Viatris supplied medicines to approximately 1 billion patients globally. Tillotts Pharma launches new dosage strength of Octasa in Canada Octasa 1600 mg (mesalazine) delayed-release tablets is a first-line treatment for moderately active ulcerative colitis. First Previous 5 6 7 8 9 Next Last